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Purpose. To determinewhether Ski-interacting protein (SKIP) regulates TGF-𝛽1-stimulated expression of urokinase-type plasmino-
gen activator (uPA),matrixmetalloproteinase-9 (MMP-9), and uPA Inhibitor (PAI-1) in the androgen-independent human prostate
cancer cell model.Materials and Methods. PC-3 prostate cancer cell line was used. The role of SKIP was evaluated using synthetic
small interference RNA (siRNA) compounds. The expression of uPA, MMP-9, and PAI-1 was evaluated by zymography assays,
RT-PCR, and promoter transactivation analysis. Results. In PC-3 cells TGF-𝛽1 treatment stimulated uPA, PAI-1, and MMP-9
expressions.Theknockdownof SKIP inPC-3 cells enhanced the basal level of uPA, andTGF-𝛽1 treatment inhibited uPAproduction.
Both PAI-1 and MMP-9 production levels were increased in response to TGF-𝛽1. The ectopic expression of SKIP inhibited
both TGF-𝛽1-induced uPA and MMP-9 promoter transactivation, while PAI-1 promoter response to the factor was unaffected.
Conclusions. SKIP regulates the expression of uPA, PAI-1, andMMP-9 stimulated by TGF-𝛽1 in PC-3 cells.Thus, SKIP is implicated
in the regulation of extracellular matrix degradation and can therefore be suggested as a novel therapeutic target in prostate cancer
treatment.
1. Introduction
Transforming growth factor 𝛽1 (TGF-𝛽1) is implicated in the
regulation of cell proliferation, differentiation, andmigration,
as well as extracellular matrix (ECM) production, apoptosis
and tumorigenesis [1]. TGF-𝛽1 is frequently overexpressed in
carcinoma cells, including prostate cancer cells, and leads to
paracrine stimulation and modification of cellular and extra-
cellular matrix components of tumour microenvironment
[2]. The urokinase-type plasminogen activator (uPA) system
is thought to play a key role in cancer invasion andmetastasis.
uPA is a secreted serine proteinase that converts plasminogen
to plasmin, a trypsin-like serine proteinase, which in turn
can degrade a wide variety of ECM components and enable
the tumour cells to penetrate the basement membrane, by
facilitating cell migration and invasiveness [3]. uPA is tightly
controlled by the specific serpin inhibitor PAI-1, which is
also upregulated in cancer. PAI-1 can promote cell migration
and angiogenesis independent of its effects on uPA-activated
plasmin [4].
Matrix metalloproteinases (MMPs) have also been
regarded as criticalmolecules in assisting tumour cells during
metastasis. MMP-9, a member of the type IV collagenases, is
known to influence cell proliferation, differentiation, angio-
genesis, apoptosis and metastasis. After activation, MMP-9
is involved in proteolytic degradation of the ECM [5].
Increased expression of uPA, PAI-1, andMMP-9 reported
in cancer has been related to poor tumour differentiation,
invasive stage of cancer, poor patient prognosis, metastasis to
secondary organs, and shorter survival time [3, 5–8]. In addi-
tion, in prostate cancer cells TGF-𝛽1 stimulates the expression
and activity of uPA, PAI-1, and MMP-9, resulting in a net
increment of pericellular plasminogen activation, increased
activation of MMP-9, and finally increased tumour cell
invasion and metastasis [9, 10].
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The signalling pathways by which TGF-𝛽 exerts its effects
on cancer cell migration and invasion are gradually being
elucidated. Recently, it has been reported that Ski-interacting
protein (SKIP) interacts with Smad2,3 to enhance TGF-𝛽-
dependent transcription, suggesting its regulatory role in cell
growth and differentiation through the TGF-𝛽 pathway [11].
SKIP is a well-conserved transcriptional adaptor protein that,
depending on the cellular context, functions to recruit either
activation or repression complexes to mediate multiple sig-
nalling pathways involved in the control of cell proliferation
and differentiation [12]. However, its precise role in the stim-
ulation of tumorigenesis by TGF-𝛽1 is poorly understood. In
this study, we investigated whether SKIP regulates the TGF-
𝛽1-induced extracellular matrix degrading system uPA/PAI-1
and MMP-9 expression in prostate carcinoma PC-3 cell line.
2. Material and Methods
2.1. Cell Culture. The human prostatic carcinoma cell line
(PC-3) was obtained from the ATCC (Mannassas, VA) and
cultured in DMEM : F12 (1 : 1) supplemented with 10% Foetal
Bovine Serum. For TGF-𝛽1 treatments, human recombinant
TGF-𝛽1 (R&D, Minneapolis, MN) was used at a 5 ng/mL.
2.2. Antibodies. SKIP (C-15) and Smad2/3 ((FL-425): sc-
8332) rabbit polyclonal antibodies were purchased fromSanta
Cruz Biotechnology (CA, USA). The p-Smad3 rabbit poly-
clonal antibody was purchased from Calbiochem, (Darm-
stadt, Germany). Anti-HA and secondary antibodies coupled
to horseradish peroxidase were purchased from Sigma (Saint
Louis MO, USA).
2.3. Plasmids and siRNA. HA-SKIP expressing plasmid was
kindly provided by Dr. M. Hayman (Stony Brook University,
USA).Human SKIP siRNA (sc-37164) and control siRNA (sc-
37007) were purchased from Santa Cruz Biotechnology. uPA
promoter (+2062 to +27) in luciferase reporter gene plasmid
pGL2 basic (p-uPA-Luc) was a generous gift from Dr. Soishi
Kojima from the Institute of Physical and Chemical Research
(RIKEN), Tsukuba, Ibaraki, Japan. MMP-9 promoter con-
struction was kindly provided by Dr. Takashi Kobayashi
(Chiba University School of Medicine, USA). The promoter
of PAI-1, p-800-luc (+71 to −800) was kindly provided by Dr.
C. Bernabeu (CIB, Spain).
2.4. Transient Transfections and Reporter GeneMeasurements.
PC-3 cells seeded in 24 well plates (∼2 × 104 cells/well) were
transfected with 500 ng/well of promoter luciferase construc-
tions and 25 ng/well of SV40-𝛽-Gal as internal control for
transfection efficiency. Transfected cells were treated with
TGF-𝛽1 for 24 h. Firefly luciferase activity (Promega, Adison
WI, USA) was standardized for 𝛽-galactosidase activity
(Tropix, Bedford, MA, USA). For SKIP knockdown experi-
ments, PC-3 cells grown in 6 well plates (∼3 × 105 cells/well)
were transfected with 20 nM of SKIP siRNA or noneffective
control siRNA.
2.5. Western Blot, Zymography, and RT-PCR Assays. Western
blots were performed as described elsewhere [13]. MMP-9
and uPA activities were assayed in serum-free media condi-
tioned for 24 h in cell cultures treated or not with TGF-𝛽1.
Conditioned media were subjected to SDS-PAGE zymogra-
phy in gels containing 1mg/mL gelatine forMMP-9 or casein-
zymography assay for uPA, as reported previously [14].
Total RNAwas obtained using Trizol and complementary
DNAwas generated by the SuperScript First-Strand Synthesis
System for RT-PCR (Invitrogen, Carlsbad, CA, USA) using
oligo (dT) primer. The following primers were used in this
study: SKIP: 5󸀠-GCG-CTC-ACC-AGC-TTT-TTA-CCT-
GCA-CC-C-3󸀠 Forward, 5󸀠-CAC-GAC-AGG-CGC-AGG-
AGG-AGA-AGC-3󸀠 Reverse, 700 bp; MMP-9: 5󸀠-GAG-ACC-
GGT GAG-CTG-GAT-AG 3󸀠 Forward, 5󸀠 TCG-AAG-ATG-
AAG-GGG-AAG-TG 3󸀠 Reverse, 500 kb; PAI-1: 5󸀠 CCA-
CTT-CTT-CAG-GCT-GTT-CC 3󸀠 Forward, 5󸀠 GCA-GTT-
CCA-GGA-TGT-CGT-AG 3󸀠 Reverse, 350 kb; and GAPDH:
5󸀠ACC-ACA-GTC-CAT-GCC-ATC-AC 3󸀠 Forward, 5󸀠 TCC-
ACC-ACC-CTG-TTG-CTG-TA 3󸀠 Reverse, 450 bp. Products
were obtained after 30–35 cycles of amplification and
electrophoresed in 1.2% agarose gels.
2.6. Statistics. Data are given as means ± SEM from at least
three independent experiments. Asterisks (∗) denote signifi-
cant differences at a value of 𝑃 < 0.05. Horizontal brackets
cover the groups that are being compared for statistical
significance.
3. Results
3.1. SKIP Expression and TGF-𝛽1-Induced uPA, MMP-9,
and PAI-1 Production in PC-3 Cells. First we examined the
expression of SKIP in prostate cancer cells bywestern blot and
RT-PCR analysis. Figure 1(a) shows that PC-3 cells express
both SKIP mRNA and protein. Next, we determined the
capacity of TGF-𝛽1 to modulate the production of extracel-
lular matrix degrading enzymes, uPA and MMP-9, as well as
uPA inhibitor PAI-1 in PC-3 cells. TGF-𝛽1 greatly enhanced
the production of uPA andMMP-9, as determined by zymog-
raphy assays (Figure 1(b)), as well as the expression of PAI-1
mRNA transcript determined by RT-PCR (Figure 1(c)).
3.2. Knockdown of SKIP by siRNA in PC-3 Cells. To analyze
whether SKIP participates in the effects of TGF-𝛽1 on PC-
3 cells, we subjected the cells to siRNA-mediated down-reg-
ulation of SKIP. As observed in Figure 1(d), the transfection
with siRNA (20 nM) produced a dramatic depletion of SKIP
expression compared with control siRNA transfected cells.
We further analyzed the functionality of SKIP knockdown
through the Smad3 activation by TGF-𝛽1. As Figure 1(e)
shows, the silencing of SKIP in PC-3 cells led to strong
repression of TGF-𝛽1-induced phosphorylation of Smad3















































































Figure 1: SKIP and TGF-𝛽1-induced uPA, PAI-1, and MMP-9 expressions in PC-3 cells. The effect of SKIP knockdown on TGF-𝛽1-induced
Smad3 phosphorylation in PC-3 cells. (a) Expression of SKIP in PC-3 cells treated with TGF-𝛽1 determined by Western blot and RT-PCR;
𝛼-tubulin and GADPH were used as a control of protein and cDNA loading, respectively. (b) Zymography analysis of uPA and MMP-9 in
PC-3 cells treated with TGF-𝛽1 for 24 h. (c) RT-PCR analysis for PAI-1 expression in PC-3 cells treated with TGF-𝛽1 for 24 h. GADPH was
used as housekeeper gene to verify the equal amount of cDNA in each sample. (d) SKIP siRNA knockdown in PC-3 cells determined by
Western Blot. Cells were transfected with control siRNA (siR-C) or siRNA against SKIP (siR-SKIP). (e) Smad3 phosphorylation after 60min
of TGF-𝛽1 treatment, determined by Western Blot in siR-C or siR-SKIP transfected cells.
3.3. SKIP Modulates uPA and PAI-1 Expressions. To analyze
whether SKIP is involved in TGF-𝛽1-induced uPA expression
in PC-3 cells, the activity of uPA secreted into the conditioned
media of SKIP siRNA transfected cells was studied by
zymography assay. In the SKIP-silenced cells, an enhanced
production of the basal level of uPAwas detected, while TGF-
𝛽1 treatment resulted in a dramatic inhibition of uPA expres-
sion, whereas in cells transfected with control siRNA TGF-
𝛽1 enhanced uPA production (Figure 2(a)). Intriguingly, the
ectopic expression of SKIP also strongly inhibited TGF-𝛽1-
induced uPA promoter transactivation (Figure 2(b)).
Additionally, SKIP knockdown enhanced the basal level
of PAI-1 mRNA expression, which was slightly modified by
TGF-𝛽1 reaching the level of PAI-1 expression in control cells
after TGF-𝛽1 treatment (Figure 3(a)). Interestingly, when we
determined the effect of the ectopic expression of SKIP on
PAI-1 promoter, we did not find significant changes in the
induction of the transactivation by TGF-𝛽1 compared with
control transfected cells (Figure 3(b)).
3.4. SKIP Silencing Enhances TGF-𝛽1-InducedMMP-9 Expres-
sion. Our next goal was to analyze whether SKIP modulates
TGF-𝛽1-induced MMP-9 production. As shown in Fig-
ure 4(a), the stimulation of MMP-9 production by TGF-𝛽1,
determined by zymography, was strongly enhanced in SKIP-
depleted cells relative to stimulated control cells. This result
paralleled with that obtained by RT-PCR analysis, where the
expression of the MMP-9 mRNA transcript was enhanced
in SKIP siRNA-transfected cells under TGF-𝛽1 treatment
comparedwith control siRNA transfected cells. Furthermore,
the effect of the ectopic expression of SKIP inhibited the
stimulus of TGF-𝛽1 on MMP-9 promoter activity when



















































































Figure 2: Effect of SKIP knockdown on TGF-𝛽1-induced uPA expression. (a) Secreted uPA activity determined by zymography in the serum-
free conditionedmedia of PC-3 cells transfected either with control siRNA (siR-C) or siRNA-SKIP (siR-SKIP), and treated or not with TGF-𝛽1
for 24 h. (b) Transactivation of uPA promoter in PC-3 cells transiently transfected with uPA promoter construction and siR-C, siR-SKIP or
SKIP-Ha tagged expressing vector (SKIP-V) and treated with TGF-𝛽1 for 48 h. The correct expression of ectopic SKIP-HA in PC-3 cells was






































































Figure 3: Effect of SKIP knockdown onTGF-𝛽1-induced PAI-1 expression. (a) Expression of PAI-1mRNA transcripts evaluated by RT-PCR in
PC-3 cells transfected with either control siRNA (siR-C) or siRNA-SKIP (siR-SKIP) before and after stimulation (24 h) with TGF-𝛽1. GAPDH
was amplified as a control for the amount of cDNA present in each sample. (b) Transactivation of PAI-1 promoter in PC-3 cells is transiently
transfected with empty vector (EV) as a control or SKIP-Ha tagged expressing vector (SKIP-V). MMP-9 promoter activity was assayed in cells
unstimulated and stimulated with TGF-𝛽1 for 48 h. 𝛽-Galactosidase was used as an internal control of transfection.
4. Discussion
TGF-𝛽 is a multifunctional cytokine with an established role
as a prometastatic agent in advanced cancer, and its expres-
sion has been negatively correlated with patient prognosis in
malignant human prostate tumours [2]. The ability of TGF-𝛽
to stimulate invasion may represent an important contribu-
tion to the carcinogenic process in the prostate. Since TGF-
𝛽1 stimulates the invasiveness of tumour cells [1], it is impor-
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Figure 4: Effect of SKIP knockdown on TGF-𝛽1-induced MMP-9 production. (a) MMP-9 zymography assay and RT-PCR analysis in PC-3
cells transfected with either siR-C or siR-SKIP and treated with TGF-𝛽1 for 24 h. GAPDH was amplified as RT-PCR control for the amount
of cDNA present in each sample. (b) Transactivation of MMP-9 promoter in PC-3 cells is transiently transfected with empty vector (EV) or
SKIP-Ha tagged expressing vector (SKIP-V). MMP-9 promoter activity was assayed in cells unstimulated and stimulated with TGF-𝛽1 for
48 h. 𝛽-Galactosidase was used as an internal control of transfection.
signalling of this factor in transformed cells. Recently, the
Ski-interacting protein (SKIP) has been shown to modulate
Smads’ activities in TGF-𝛽1 signalling pathway [11], even
though its role on TGF-𝛽1-induced human cell malignance
is not well elucidated yet.
In the present work, we analyzed the role of SKIP
in TGF-𝛽1-stimulated expression of extracellular degrading
proteinases uPA, MMP-9 and the inhibitor of uPA, PAI-1.
These proteins are highly involved in tumour cell invasion
andmetastasis and are also known as poor prognosismarkers
in human cancer [3, 5–8]. As a cellular model we used the
human prostate cancer PC-3 cell line, which was established
from a prostatic adenocarcinoma metastasis in the bone,
retaining in vitro features common to neoplastic cells of
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epithelial origin [14]. We observed that PC-3 cells express
detectable levels of SKIP mRNA transcript and SKIP protein,
and under TGF-𝛽1 treatment the cells are induced to increase
the production of uPA, MMP-9, and PAI-1 (Figure 1), which
is in agreement with several previous reports [15–17].
The knockdown of SKIP increased basal production
of uPA, while it decreased uPA production after TGF-𝛽1
treatment (Figure 2). Given that SKIP depletion decreased
Smad3 activation [13], and that we have previously reported
Smad3 as essential for TGF-𝛽1-induced uPA in transformed
cells [18], we can speculate that the reduction of Smad3
activation by TGF-𝛽1 may inverse the cell response to the
growth factor, while in basal conditions the effect of SKIP on
uPA expression may be independent of Smad3 signalling.
The activity of uPA is also regulated by the expression of
its inhibitor PAI-1 [3, 4]. Interestingly, the downregulation
of SKIP enhanced basal production of PAI-1 and this level
was unaffected by TGF-𝛽1 (Figure 3). A conceivable spec-
ulation for this result might be the involvement of SKIP in
Retinoblastoma (Rb) inhibition. In hypophosphorylated state
Rb is in complex with E2F, a cell cycle regulator, whereas
when Rb is phosphorylated by CDKs, E2F is released and in
free form acts as an inhibitor of PAI-1 expression [19]. Low
expression of SKIP may keep Rb/E2F in complex, which
could then result in the increment of PAI-1 expression
independent of TGF-𝛽1 stimulation. In addition, E2F is also a
negative regulator of uPA expression, which could, in part,
explain the enhanced basal level of uPA expression under
SKIP depletion. Thus, SKIP depletion may affect basal uPA
and PAI-1 expression independently of Smad3 in PC-3 cells.
Additionally, we observed that PC-3 cells increase the
expressions of MMP-9 under TGF-𝛽1 treatment and that the
reduction of SKIP enhanced the TGF-𝛽1-induced MMP-9
expression, while the ectopic expression of SKIP inhibited
MMP-9 promoter transactivation (Figure 4). The effect of
SKIP downregulation on TGF-𝛽1-induced MMP-9 in part
may be explained by the reduction of Smad3 activation,which
could be necessary to regulate the adequate level of MMP-
9 expression, whereas low levels of Smad3 activation may
deregulate the control of MMP-9 expression in PC-3 cells
in response to TGF-𝛽1. This observation is supported by
reports in which the missense mutations of the Smad3 gene
or depletion of Smad3 in knockout mice showed increased
MMP-9 production [20, 21].
5. Conclusions
The results presented here show that SKIP regulates the
expression of uPA, PAI-1, andMMP-9 in response to TGF-𝛽1
in PC-3 cells, implicating SKIP in the regulation of extracellu-
lar matrix degradation. Further studies should be performed
in order to understand the magnitude of the possible role of
SKIP in prostate cancer progression. Investigations commit-
ted to determining the level of SKIP expression in prostate
cancer cells with different levels of malignance as well as
analysis of clinical prostate cancer samples for its expression
and distribution would be of high interest.
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